Gene Therapy using Intramuscular Administration of AMG0001 in Patients with Peripheral Arterial Disease

Trial Profile

Gene Therapy using Intramuscular Administration of AMG0001 in Patients with Peripheral Arterial Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 May 2016

At a glance

  • Drugs Beperminogene perplasmid (Primary)
  • Indications Arteriosclerosis obliterans; Thromboangiitis obliterans
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Sep 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 01 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top